Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment;… Read more
Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) - Total Assets
Latest total assets as of September 2025: CN¥8.81 Billion CNY
Based on the latest financial reports, Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) holds total assets worth CN¥8.81 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Sunshine Guojian Pharmaceutical Shanghai Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd's total assets of CN¥8.81 Billion consist of 44.6% current assets and 55.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.7% |
| Accounts Receivable | CN¥147.17 Million | 2.5% |
| Inventory | CN¥229.60 Million | 3.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥452.50 Million | 7.6% |
| Goodwill | CN¥639.58K | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Sunshine Guojian Pharmaceutical Shanghai Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunshine Guojian Pharmaceutical Shanghai Co Ltd's current assets represent 44.6% of total assets in 2024, an increase from 23.3% in 2006.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 7.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 34.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 7.6% of total assets.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Competitors by Total Assets
Key competitors of Sunshine Guojian Pharmaceutical Shanghai Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sunshine Guojian Pharmaceutical Shanghai Co Ltd generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Sunshine Guojian Pharmaceutical Shanghai Co Ltd generates $ 11.81 in net profit.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 3.51 | 11.14 |
| Quick Ratio | 1.97 | 3.24 | 10.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.01 Billion | CN¥ 1.91 Billion | CN¥ 2.84 Billion |
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sunshine Guojian Pharmaceutical Shanghai Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.10 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | CN¥5.97 Billion |
| Market Capitalization | $723.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunshine Guojian Pharmaceutical Shanghai Co Ltd's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sunshine Guojian Pharmaceutical Shanghai Co Ltd's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sunshine Guojian Pharmaceutical Shanghai Co Ltd (2006–2024)
The table below shows the annual total assets of Sunshine Guojian Pharmaceutical Shanghai Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.97 Billion | +12.44% |
| 2023-12-31 | CN¥5.31 Billion | +4.05% |
| 2022-12-31 | CN¥5.10 Billion | +4.29% |
| 2021-12-31 | CN¥4.89 Billion | -1.31% |
| 2020-12-31 | CN¥4.95 Billion | +49.21% |
| 2019-12-31 | CN¥3.32 Billion | -10.34% |
| 2018-12-31 | CN¥3.70 Billion | +10.77% |
| 2017-12-31 | CN¥3.34 Billion | +15.71% |
| 2016-12-31 | CN¥2.89 Billion | +12.31% |
| 2015-12-31 | CN¥2.57 Billion | +12.29% |
| 2014-12-31 | CN¥2.29 Billion | +0.65% |
| 2013-12-31 | CN¥2.28 Billion | +16.45% |
| 2012-12-31 | CN¥1.95 Billion | +23.26% |
| 2011-12-31 | CN¥1.59 Billion | +40.54% |
| 2010-12-31 | CN¥1.13 Billion | +52.03% |
| 2009-12-31 | CN¥742.18 Million | +19.94% |
| 2008-12-31 | CN¥618.78 Million | +15.07% |
| 2007-12-31 | CN¥537.74 Million | +4.04% |
| 2006-12-31 | CN¥516.86 Million | -- |